JP2024500377A - Ｐｄｅ４分解剤、医薬組成物、及び治療的応用 - Google Patents
Ｐｄｅ４分解剤、医薬組成物、及び治療的応用 Download PDFInfo
- Publication number
- JP2024500377A JP2024500377A JP2023535990A JP2023535990A JP2024500377A JP 2024500377 A JP2024500377 A JP 2024500377A JP 2023535990 A JP2023535990 A JP 2023535990A JP 2023535990 A JP2023535990 A JP 2023535990A JP 2024500377 A JP2024500377 A JP 2024500377A
- Authority
- JP
- Japan
- Prior art keywords
- mixture
- ethoxy
- formula
- tautomers
- methoxyphenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124877P | 2020-12-14 | 2020-12-14 | |
| US63/124,877 | 2020-12-14 | ||
| PCT/US2021/062995 WO2022132603A1 (en) | 2020-12-14 | 2021-12-13 | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500377A true JP2024500377A (ja) | 2024-01-09 |
| JP2024500377A5 JP2024500377A5 (https=) | 2024-12-20 |
Family
ID=79288082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023535990A Pending JP2024500377A (ja) | 2020-12-14 | 2021-12-13 | Ｐｄｅ４分解剤、医薬組成物、及び治療的応用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240124418A1 (https=) |
| EP (1) | EP4259621A1 (https=) |
| JP (1) | JP2024500377A (https=) |
| KR (1) | KR20230157936A (https=) |
| CN (1) | CN117203196A (https=) |
| AU (1) | AU2021402911A1 (https=) |
| CA (1) | CA3201965A1 (https=) |
| IL (1) | IL303611A (https=) |
| TW (1) | TW202237580A (https=) |
| WO (1) | WO2022132603A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021119571A1 (en) * | 2019-12-12 | 2021-06-17 | Biotheryx, Inc. | Pde4 inhibitors, pharmaceutical compositions, and therapeutic applications |
| WO2024168096A2 (en) * | 2023-02-07 | 2024-08-15 | Biotheryx, Inc. | Pde4 degraders, pharmaceutical compositions, and therapeutic applications |
| US20240327381A1 (en) * | 2023-02-08 | 2024-10-03 | Celgene Corporation | Compounds and Compositions for Selective Degradation of Engineered Proteins |
| AU2024323358A1 (en) * | 2023-08-17 | 2026-02-26 | Katalytic Therapeutics, Inc. | Pde4 protein degraders, pharmaceutical compositions, and therapeutic applications |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06509820A (ja) * | 1992-06-15 | 1994-11-02 | セルテック リミテッド | 選択的ホスホジエステラーゼ■阻害剤としての三置換フェニル誘導体 |
| JP2002528496A (ja) * | 1998-10-30 | 2002-09-03 | セルジーン コーポレイション | 置換フェネチルスルホン類およびＴＮＦαレベルの減少方法 |
| JP2004500346A (ja) * | 1999-11-12 | 2004-01-08 | セルジーン コーポレイション | 薬剤活性のあるイソインドリン誘導体 |
| JP2005525386A (ja) * | 2002-03-20 | 2005-08-25 | セルジーン・コーポレーション | （＋）−２−［１−（３−エトキシ−４−メトキシフェニル）−２−メチルスルホニルエチル］−４−アセチルアミノイソインドリン−１，３−ジオン、その使用方法及び組成物 |
| JP2017513862A (ja) * | 2014-04-14 | 2017-06-01 | アルビナス インコーポレイテッド | イミド系タンパク質分解モジュレーター及び関連する使用方法 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| US5055252A (en) | 1989-01-12 | 1991-10-08 | Superior Walls Of America, Ltd. | Method of constructing an integrated concrete wall structure |
| US5585112A (en) | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
| IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
| US5543390A (en) | 1990-11-01 | 1996-08-06 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University | Covalent microparticle-drug conjugates for biological targeting |
| GB9212693D0 (en) * | 1992-06-15 | 1992-07-29 | Celltech Ltd | Chemical compounds |
| US6274552B1 (en) | 1993-03-18 | 2001-08-14 | Cytimmune Sciences, Inc. | Composition and method for delivery of biologically-active factors |
| US5523092A (en) | 1993-04-14 | 1996-06-04 | Emory University | Device for local drug delivery and methods for using the same |
| US5985307A (en) | 1993-04-14 | 1999-11-16 | Emory University | Device and method for non-occlusive localized drug delivery |
| US6004534A (en) | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
| US5759542A (en) | 1994-08-05 | 1998-06-02 | New England Deaconess Hospital Corporation | Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases |
| US5660854A (en) | 1994-11-28 | 1997-08-26 | Haynes; Duncan H | Drug releasing surgical implant or dressing material |
| US5525907A (en) | 1995-03-17 | 1996-06-11 | Hughes Missile Systems Company | Active impulse magnetometer with bipolar magnetic impulse generator and fast fourier transform receiver to detect sub-surface metallic materials |
| US6316652B1 (en) | 1995-06-06 | 2001-11-13 | Kosta Steliou | Drug mitochondrial targeting agents |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
| TW345603B (en) | 1996-05-29 | 1998-11-21 | Gmundner Fertigteile Gmbh | A noise control device for tracks |
| JP2000508339A (ja) | 1996-10-01 | 2000-07-04 | シーマ・ラブス・インコーポレイテッド | 味隠蔽マイクロカプセル組成物及び製造方法 |
| US6131570A (en) | 1998-06-30 | 2000-10-17 | Aradigm Corporation | Temperature controlling device for aerosol drug delivery |
| US6120751A (en) | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
| US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6048736A (en) | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
| US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
| BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
| WO2017201069A1 (en) | 2016-05-18 | 2017-11-23 | Biotheryx, Inc. | Oxoindoline derivatives as protein function modulators |
| US10040804B2 (en) | 2016-12-21 | 2018-08-07 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| US10406165B2 (en) | 2017-03-14 | 2019-09-10 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| US10513515B2 (en) | 2017-08-25 | 2019-12-24 | Biotheryx, Inc. | Ether compounds and uses thereof |
| WO2019173224A1 (en) | 2018-03-05 | 2019-09-12 | Biotheryx, Inc. | Deuterated compounds and chimeras and uses thereof |
| CA3094988A1 (en) | 2018-03-30 | 2019-10-03 | Biotheryx, Inc. | Thienopyrimidinone compounds |
| WO2019241271A1 (en) | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Fused thiophene compounds |
| WO2020102195A1 (en) | 2018-11-13 | 2020-05-22 | Biotheryx, Inc. | Substituted isoindolinones |
| CN113453681B (zh) | 2018-12-19 | 2024-10-11 | 细胞基因公司 | 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法 |
| JP2022533260A (ja) | 2019-05-24 | 2022-07-21 | バイオセリックス， インコーポレイテッド | タンパク質を標的とする化合物及びその医薬組成物並びにそれらの治療的応用 |
| WO2021119571A1 (en) * | 2019-12-12 | 2021-06-17 | Biotheryx, Inc. | Pde4 inhibitors, pharmaceutical compositions, and therapeutic applications |
-
2021
- 2021-12-13 CN CN202180093639.7A patent/CN117203196A/zh active Pending
- 2021-12-13 CA CA3201965A patent/CA3201965A1/en active Pending
- 2021-12-13 EP EP21840310.3A patent/EP4259621A1/en active Pending
- 2021-12-13 AU AU2021402911A patent/AU2021402911A1/en active Pending
- 2021-12-13 IL IL303611A patent/IL303611A/en unknown
- 2021-12-13 US US18/256,636 patent/US20240124418A1/en active Pending
- 2021-12-13 JP JP2023535990A patent/JP2024500377A/ja active Pending
- 2021-12-13 WO PCT/US2021/062995 patent/WO2022132603A1/en not_active Ceased
- 2021-12-13 TW TW110146590A patent/TW202237580A/zh unknown
- 2021-12-13 KR KR1020237023788A patent/KR20230157936A/ko active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06509820A (ja) * | 1992-06-15 | 1994-11-02 | セルテック リミテッド | 選択的ホスホジエステラーゼ■阻害剤としての三置換フェニル誘導体 |
| JP2002528496A (ja) * | 1998-10-30 | 2002-09-03 | セルジーン コーポレイション | 置換フェネチルスルホン類およびＴＮＦαレベルの減少方法 |
| JP2004500346A (ja) * | 1999-11-12 | 2004-01-08 | セルジーン コーポレイション | 薬剤活性のあるイソインドリン誘導体 |
| JP2005525386A (ja) * | 2002-03-20 | 2005-08-25 | セルジーン・コーポレーション | （＋）−２−［１−（３−エトキシ−４−メトキシフェニル）−２−メチルスルホニルエチル］−４−アセチルアミノイソインドリン−１，３−ジオン、その使用方法及び組成物 |
| JP2017513862A (ja) * | 2014-04-14 | 2017-06-01 | アルビナス インコーポレイテッド | イミド系タンパク質分解モジュレーター及び関連する使用方法 |
Non-Patent Citations (1)
| Title |
|---|
| EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 206, JPN6025043813, 19 July 2020 (2020-07-19), pages 112494, ISSN: 0005717906 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230157936A (ko) | 2023-11-17 |
| IL303611A (en) | 2023-08-01 |
| WO2022132603A1 (en) | 2022-06-23 |
| US20240124418A1 (en) | 2024-04-18 |
| CN117203196A (zh) | 2023-12-08 |
| EP4259621A1 (en) | 2023-10-18 |
| AU2021402911A1 (en) | 2023-07-06 |
| TW202237580A (zh) | 2022-10-01 |
| CA3201965A1 (en) | 2022-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240025863A1 (en) | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| JP2024500377A (ja) | Ｐｄｅ４分解剤、医薬組成物、及び治療的応用 | |
| EP4355741B1 (en) | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| TW202231269A (zh) | Kras蛋白降解劑、其醫藥組合物及其治療應用 | |
| US20240190883A1 (en) | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| US20230233562A1 (en) | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use | |
| US20240368121A1 (en) | Estrogen receptor degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| US20240190885A1 (en) | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| CN103038216A (zh) | 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途 | |
| US20250186434A1 (en) | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| US20260007685A1 (en) | Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications | |
| US20240116845A1 (en) | Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications | |
| US20250214967A1 (en) | Fak degraders, pharmaceutical compositions, and therapeutic applications | |
| US20240197888A1 (en) | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | |
| US12419962B2 (en) | Quinazolines, pharmaceutical compositions, and therapeutic applications | |
| WO2024168096A2 (en) | Pde4 degraders, pharmaceutical compositions, and therapeutic applications | |
| US12570687B2 (en) | Triterpenoid compounds, pharmaceutical compositions thereof, and their use for treating a nuclear receptor subfamily 4 group a member 1-mediated disease | |
| TWI856340B (zh) | 作為pd-l1相互作用的免疫調節劑的雜環化合物 | |
| KR20260039735A (ko) | 기능화된 아우리스타틴, 약제학적 조성물, 및 치료적 적용 | |
| JP2025541836A (ja) | ホスホロアミダートモノサッカライド、医薬組成物、並びに診断的及び治療的応用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241211 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241211 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20251021 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251028 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260421 |